For patients with metastatic triple-negative breast cancer, clinical activity with Trodelvy (sacituzumab govitecan) stays consistent, researchers found. Enhertu (trastuzumab deruxtecan) in a subgroup with HER2-low disease also continued to demonstrate promising clinical activity after administration of Trodelvy, suggesting the use […]
Trodelvy Is Effective in Real-World Patients With Breast Cancer Subset Read More »
Keytruda plus radiation therapy shows promising results for breast cancer patients, particularly those with TNBC and HR+/HER2- subtypes. Among patients with triple negative breast cancer (TNBC) and hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer, preoperative radiation therapy
Keytruda Plus Radiation Therapy Shows Promise for Breast Cancer Patients Read More »
It’s important for cancer survivors who were treated with chemotherapy and radiation to monitor themselves for symptoms of cardiovascular disease, an expert told CURE®. The side effects of cancer treatment can be overwhelming for patients and their families. It’s important
Identifying Cardiovascular Disease Risk in Cancer Survivors Read More »
The rate at which PSA levels rise after hormonal therpay for prostate cancer can predict treatment response. For patients with recurrent and advanced prostate cancer, hormonal therapies may prove to be a viable option in both intermittent and continuous administration;
Rise in PSA Levels May Predict Treatment Response in Prostate Cancer Read More »
A new study reveals that older adults with cancer, particularly those with metastatic or hematological cancers, may demonstrate an elevated risk of cardiovascular disease. Among older adults with cancer, incidence of cardiovascular disease (CVD), including myocardial infarction (MI), hospitalization for
Incidence of Cardiovascular Disease May Increase in Older Adults With Cancer Read More »
TULSA is a promising prostate cancer treatment that effectively targets tumors while minimizing side effects and preserving healthy tissue. Patients with prostate cancer demonstrated reduced tumor volume and PSA levels, a key marker of prostate cancer progression, and experienced improved
Transurethral Ultrasound Ablation a Promising Prostate Cancer Treatment Read More »
Dato-DXd demonstrated significant improvements in progression-free survival for patients with inoperable or metastatic HR-positive/HER2-negative breast cancer. Datopotamab deruxtecan (Dato-DXd) demonstrated significant improvements in progression-free survival (PFS; time a person lives without their disease getting worse) with a manageable safety profile
Dato-DXd May Improve Progression-Free Survival in Breast Cancer Subset Read More »
Lazcluze shows promise as a potential treatment option for patients with EGFR-variant NSCLC, demonstrating significant central nervous system activity in both T790M-positive and -negative cases. For patients with metastatic EGFR-variant non-small cell lung cancer (NSCLC), Lazcluze (lazertinib) has shown significant
Lazcluze Shows Central Nervous System Activity In EGFR-Variant NSCLC Read More »
In patients with metastatic (spreading) colorectal cancer (mCRC), adding high-dose vitamin D3 to standard treatment did not improve progression-free survival (PFS; time a person lives without their disease getting worse) versus the standard dose of vitamin D3, except possibly in
High vs Low Dose of Vitamin D May Not Impact Treating mCRC Read More »
The study found that Opdivo and Abraxane were effective and safe in treating muscle-invasive bladder cancer. Opdivo (nivolumab) with Abraxane (nab-paclitaxel) could expand the therapeutic opportunities of immune chemotherapy in patients with muscle-invasive bladder cancer (MIBC), according to results from
Opdivo with Abraxane May Expand Therapeutic Opportunities For MIBC Read More »
